GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate GLPG2737 administered orally b.i.d. for 28 days to adult male and female subjects with a confirmed diagnosis of cystic fibrosis homozygous for the F508del CFTR mutation and on stable treatment with Orkambi.
Epistemonikos ID: 2c4cdb9eaf32a75167a4066dcd11e0b77a12e7fa
First added on: May 21, 2024